Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case‒control study

Inhibitor development is a major complication of treatment with factor VIII concentrates in nonsevere haemophilia A. It has been suggested that plasma‐derived factor VIII (FVIII) concentrates elicit fewer inhibitors than recombinant FVIII concentrates, but studies in severe haemophilia A patients ha...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Main Authors: van Velzen, Alice S., Eckhardt, Corien L., Peters, Marjolein, Oldenburg, Johannes, Cnossen, Marjon, Liesner, Ri, Morfini, Massimo, Castaman, Giancarlo, McRae, Simon, van der Bom, Johanna G., Fijnvandraat, Karin
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Platelets, Haemostasis and Thrombosis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318706/
https://ncbi.nlm.nih.gov/pubmed/32201943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16490
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares